PT3220909T - Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano - Google Patents

Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano

Info

Publication number
PT3220909T
PT3220909T PT158611897T PT15861189T PT3220909T PT 3220909 T PT3220909 T PT 3220909T PT 158611897 T PT158611897 T PT 158611897T PT 15861189 T PT15861189 T PT 15861189T PT 3220909 T PT3220909 T PT 3220909T
Authority
PT
Portugal
Prior art keywords
erythrohydroxybupropion
methods
plasma levels
drug plasma
modulating drug
Prior art date
Application number
PT158611897T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3220909(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/550,618 external-priority patent/US9198905B2/en
Priority claimed from US14/602,177 external-priority patent/US9402843B2/en
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of PT3220909T publication Critical patent/PT3220909T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT158611897T 2014-11-21 2015-05-01 Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano PT3220909T (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14/550,618 US9198905B2 (en) 2013-11-05 2014-11-21 Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US14/555,085 US9238032B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US14/554,988 US9205083B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
US14/554,947 US20150126542A1 (en) 2013-11-05 2014-11-26 Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects
US14/602,177 US9402843B2 (en) 2013-11-05 2015-01-21 Compositions and methods of using threohydroxybupropion for therapeutic purposes
US14/604,397 US9168234B2 (en) 2013-11-05 2015-01-23 Bupropion as a modulator of drug activity
US14/617,624 US9486450B2 (en) 2013-11-05 2015-02-09 Hydroxybupropion and related compounds as modulators of drug plasma levels
US14/628,062 US9402844B2 (en) 2013-11-05 2015-02-20 Methods of modulating drug plasma levels using erythrohydroxybupropion

Publications (1)

Publication Number Publication Date
PT3220909T true PT3220909T (pt) 2020-12-07

Family

ID=56014366

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158611897T PT3220909T (pt) 2014-11-21 2015-05-01 Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano

Country Status (22)

Country Link
EP (2) EP3763372A1 (enExample)
JP (5) JP6602863B2 (enExample)
KR (7) KR102253986B1 (enExample)
CN (2) CN107205998A (enExample)
AU (4) AU2015350559C1 (enExample)
CA (3) CA3232022A1 (enExample)
CY (1) CY1123571T1 (enExample)
DK (1) DK3220909T3 (enExample)
ES (1) ES2835304T3 (enExample)
HR (1) HRP20201855T1 (enExample)
HU (1) HUE052609T2 (enExample)
IL (4) IL314982A (enExample)
LT (1) LT3220909T (enExample)
MX (3) MX2021001442A (enExample)
MY (1) MY189466A (enExample)
PL (1) PL3220909T3 (enExample)
PT (1) PT3220909T (enExample)
RS (1) RS61113B1 (enExample)
SG (2) SG11201704066VA (enExample)
SI (1) SI3220909T1 (enExample)
SM (1) SMT202000639T1 (enExample)
WO (1) WO2016081027A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
WO2016081027A1 (en) * 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN114712358A (zh) * 2019-01-07 2022-07-08 安泰赛普生物风投二代有限责任公司 用于治疗抑郁症的右美沙芬和安非他酮的组合
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN114340608B (zh) * 2020-07-20 2023-10-31 深圳信立泰药业股份有限公司 一种药物组合物及其应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
IL298972A (en) * 2013-11-05 2023-02-01 Antecip Bioventures Ii Llc Preparations containing dextromethorphan and bupropion or similar substances and their uses
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
WO2016081027A1 (en) * 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion

Also Published As

Publication number Publication date
WO2016081027A1 (en) 2016-05-26
MX2017006653A (es) 2017-10-31
JP2021066744A (ja) 2021-04-30
KR102640586B1 (ko) 2024-02-23
ES2835304T3 (es) 2021-06-22
AU2019201548B2 (en) 2020-11-26
CA2968371A1 (en) 2016-05-26
CA3232022A1 (en) 2016-05-26
IL280905A (en) 2021-04-29
EP3220909A1 (en) 2017-09-27
SI3220909T1 (sl) 2021-01-29
MX2023000320A (es) 2023-02-09
SG10201911873XA (en) 2020-02-27
RS61113B1 (sr) 2020-12-31
HRP20201855T1 (hr) 2021-04-02
IL280905B (en) 2022-11-01
JP2020023527A (ja) 2020-02-13
HUE052609T2 (hu) 2021-05-28
KR20220038820A (ko) 2022-03-29
IL314982A (en) 2024-10-01
MY189466A (en) 2022-02-15
KR20240027872A (ko) 2024-03-04
JP2023041862A (ja) 2023-03-24
AU2021200981A1 (en) 2021-03-11
EP3220909A4 (en) 2018-07-11
IL252417B (en) 2021-03-25
AU2015350559C1 (en) 2019-07-11
CY1123571T1 (el) 2022-03-24
EP3220909B1 (en) 2020-09-02
CA3082645A1 (en) 2016-05-26
IL297349B2 (en) 2025-01-01
CA2968371C (en) 2020-08-18
AU2021200981B2 (en) 2024-06-20
KR102524253B1 (ko) 2023-04-20
JP2017535563A (ja) 2017-11-30
KR20210059788A (ko) 2021-05-25
CN111297860A (zh) 2020-06-19
JP7226839B2 (ja) 2023-02-21
JP2025105965A (ja) 2025-07-10
KR20250092295A (ko) 2025-06-23
AU2019201548C1 (en) 2021-09-16
LT3220909T (lt) 2021-01-25
PL3220909T3 (pl) 2021-04-06
SMT202000639T1 (it) 2021-01-05
IL280905B2 (en) 2023-03-01
IL252417A0 (en) 2017-07-31
KR101931896B1 (ko) 2018-12-21
EP3763372A1 (en) 2021-01-13
AU2015350559B2 (en) 2018-12-06
AU2015350559A1 (en) 2017-06-08
MX2021001442A (es) 2023-01-05
JP6842129B2 (ja) 2021-03-17
KR102253986B1 (ko) 2021-05-21
KR102822654B1 (ko) 2025-06-18
KR20170088926A (ko) 2017-08-02
AU2019201548A1 (en) 2019-03-28
DK3220909T3 (da) 2020-11-23
IL297349A (en) 2022-12-01
CN107205998A (zh) 2017-09-26
IL297349B1 (en) 2024-09-01
KR102376868B1 (ko) 2022-03-18
CA3082645C (en) 2024-04-16
AU2024219871A1 (en) 2024-10-10
KR20230056795A (ko) 2023-04-27
SG11201704066VA (en) 2017-06-29
HK1243323A1 (zh) 2018-07-13
KR20180136003A (ko) 2018-12-21
JP6602863B2 (ja) 2019-11-06

Similar Documents

Publication Publication Date Title
IL252417B (en) Use of erythrohydroxybupropion to increase plasma drug level
ZA201802663B (en) Modulators of kras expression
IL259421B (en) ror - gamma modulators
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
GB201701673D0 (en) Methods of well treatment
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
PL3218910T3 (pl) Przepust
GB201407322D0 (en) Gene therapy
EP3235357C0 (en) EXECUTION
GB201416832D0 (en) Methods of treatment
EP3236963A4 (en) Method of treatment
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
EP3226864A4 (en) Methods of treating fibrosis
IL247234A0 (en) Caspase-6 modulators
GB201412010D0 (en) Treatment of hypertransaminasemia
SG11201607445QA (en) Methods of modulating wars2
GB201407806D0 (en) Treatment of fibrosis
AU2014904206A0 (en) Treatment of fibrosis
AU2014905194A0 (en) Method of Treatment
AU2014904907A0 (en) Method of Treatment
AU2014904371A0 (en) Method of treatment
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors
TWM489666U (en) Structure of goggles